Table 2: Pharmacokinetics of empagliflozin and glimepiride when given alone and in combination in healthy male subjects


Parameter

Test

Reference

Geometric mean ratio [GMR]
(%)

90% CI for GMR

 

gCV
(%)

Lower limit (%)

Upper limit
(%)


Empagliflozin

 

 

 

 

 

 

AUCτ,ss

Empagliflozin + glimepiride

Empagliflozin

95.2

92.0

98.5

5.5

Cmax,ss

Empagliflozin + glimepiride

Empagliflozin

95.6

88.2

103.5

12.9

Glimepiride

 

 

 

 

 

 

AUC0-∞

Empagliflozin + glimepiride

Glimepiride

93.3

86.1

101.0

12.9

Cmax

Empagliflozin + glimepiride

Glimepiride

104.2

89.5

121.3

24.8


Data are from the pharmacokinetic set; N=16.
CI, confidence intervals; gCV, intra-individual geometric coefficient of variation;
AUCτ,ss, area under concentration-time curve of empagliflozin in plasma at steady state; Cmax,ss, maximum measured concentration of empagliflozin in plasma at steady state; AUC0-∞, area under concentration-time curve of glimepiride in plasma over time interval from 0 extrapolated to infinity; Cmax, maximum measured concentration of glimepiride in plasma.

Macha et al.Journal of Diabetes Research and Clinical Metabolism  2012 1:14DOI : 10.7243/2050-0866-1-14